Fort Lauderdale, FL, August 26, 2015 - OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, and Seoul National University Hospital Clinical Trials Center (SNUH CTC), a leading academic medical center in the Republic of Korea, announced the go-live of TrialOne the global leader in eSource and Early Phase clinic automation.
TrialOne was selected by SNUH CTC after an extensive market evaluation to automate its early phase study activities. The successful implementation will allow SNUH CTC to streamline their clinical trial processes by supporting more efficient work flows while delivering a substantial increase in the data quality and reducing the timelines of their clinical trials and related services to their clients.
“We are very delighted that OmniComm’s TrialOne has been successfully incorporated into the SNUH’s early clinical trial environment. This will dramatically increase the quality, efficiency, and speed of our research activities from subject recruitment to data management,” stated Professor Yung-Jue Bang, MD, PhD, president of the Biomedical Research Institute, SNUH, and director of SNUH CTC.
SNUH implemented TrialOne in a semi-phased approach starting with TrialOne Recruitment. This phase included a Korean database migration successfully managed by OmniComm Professional Services. Shortly thereafter, the remainder of the TrialOne suite was implemented including electronic data collection, direct data capture from devices, data and query management and sample tracking. SNUH is the first TrialOne site in Asia to go live with the full TrialOne suite.
This 52 bed Early Phase clinic and its 50 TrialOne users are anticipating at least thirty studies annually. Their first TrialOne study was a multiple dose study with data captured in both English and Korean.
“The Clinical Trials Center of Seoul National University Hospital belongs to the absolute top of clinical research institutes in East Asia. For OmniComm, the successful implementation of TrialOne at SNUH CTC is an important step in our further advancement into the Asian market,” says Wolf Ondracek, senior vice president academic and Asian markets, OmniComm Systems.
Commenting on the successful implementation, Randy Smith, chairman and CTO, OmniComm Systems, said, “This success was only possible through a strong partnership with Seoul National University Hospital, having the right team in place from both Seoul National University Hospital and OmniComm, and a strong commitment to deliver and set up Seoul National University Hospital for success. The TrialOne solution provides the platform to allow Seoul National University Hospital to execute on its strategic plan for the long term.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.